GlassScriptPhysician profile
Carly E Nicholas
NPI 1053791293
$2,077.64
in general payments reported to CMS, 2019-2025
28 companies · $39.04 in 2025
The $39.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $899 · 2023: $666 · 2024: $166 · 2025: $39.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.77 | 2021-2025 | |
| Pfizer INC. | $159.44 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.08 | 2021-2022 | |
| Amgen INC. | $135.22 | 2021-2023 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $124.57 | 2021-2023 | Emgality, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $121.98 | 2021-2024 | Breztri, Airsupra |
| Miach Orthopaedics, INC. | $120.65 | 2024 | |
| Novo Nordisk INC | $93.53 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $84.78 | 2021-2023 | Rexulti |
| Exact Sciences Corporation | $59.42 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $48.28 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $46.60 | 2022-2023 | Belsomra |
| Novartis Pharmaceuticals Corporation | $43.38 | 2021-2022 | |
| Glaxosmithkline, LLC. | $41.95 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $38.51 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $35.97 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.99 | 2022 | |
| Abbott Laboratories | $23.60 | 2023 | Freestyle Libre 2 |
| Vertex Pharmaceuticals Incorporated | $22.80 | 2025 | |
| Biogen, INC. | $16.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.33 | 2023 | |
| Kci USA, INC. | $16.30 | 2023 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Esperion Therapeutics, INC. | $14.00 | 2022 | |
| Eisai INC. | $13.66 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.62 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $12.02 | 2021 | |
| Bausch Health US, LLC | $11.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.